Karyopharm’s XPORT-EC-042 study fails to meet primary endpoint
Phase 3negativeselinexorNegative
AI Analysis
Summary
Karyopharm Therapeutics' Phase III XPORT-EC-042 trial of selinexor failed to meet its primary endpoint of progression-free survival in patients with advanced or recurrent endometrial cancer with TP53 wild-type tumours.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Failed to meet primary endpoint of progression-free survival
Importance:8/10
Sentiment:
-0.85
Phase 3 failureselinexorendometrial cancerTP53 wild-typeprogression-free survival
Related Companies
Read the original article
Published by Clinical Trials Arena on July 31, 2026 10:02 AM